KORRO BIO INC (KRRO)
Health Care · Biotechnology (RNA Therapeutics) · NASDAQ
Korro Bio is a clinical-stage genetic medicine company using its proprietary OPERA platform to develop precise, transient RNA-editing therapies for rare and complex diseases.
What KORRO BIO INC does
Korro Bio is a biopharmaceutical company developing a new class of genetic medicines using its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform. The company's technology uses RNA-editing oligonucleotides (REOs) to precisely modify mRNA transcripts to repair or create functional proteins, targeting rare and prevalent diseases without permanently altering the DNA. Key development programs include KRRO-121 for hyperammonemia (Urea Cycle Disorders and Hepatic Encephalopathy) and KRRO-111 for Alpha-1 Antitrypsin Deficiency (AATD).
Recent developments
In August 2026, the EMA granted orphan drug designation for KRRO-121 for urea cycle disorders. In May 2026, the company nominated KRRO-111 as a development candidate for AATD, and it expects to nominate a third GalNAc-conjugated program by the end of 2026.
From KORRO BIO INC's filing of 2026-08-06.
Themes: RNA editing, genetic medicines, oligonucleotide therapeutics, rare disease drug development
Fundamentals
- Price$9.44 as of 2026-10-20 close
- Market cap$139M as of 2026-08-05 (share count; price 2026-10-20)
- 1-year return-79.6% 2025-10-20 close $46.35 → 2026-10-20 close $9.44
- P/En/a negative earnings
- Net margin-1834.5% FY2025, SEC XBRL
- ROE-228.0% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+181.5% FY2025, SEC XBRL
- Beta1.79 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How KRRO compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $0 | -$20M | -$19M | -$1.07 | -$17M† | $37000† |
| Q1 FY2026 2026-03-31 | $0 | -$20M | -$20M | -$1.69 | -$16M | $21000 |
| Q4 FY2025 2025-12-31 | $1M† | -$50M† | -$50M† | -$5.32† | -$18M† | $84000† |
| Q3 FY2025 2025-09-30 | $1M | -$19M | -$18M | -$1.92 | -$17M† | $175000† |
| Q2 FY2025 2025-06-30 | $1M | -$27M | -$26M | -$2.74 | -$19M† | $140000† |
| Q1 FY2025 2025-03-31 | $3M | -$25M | -$23M | -$2.49 | -$24M | $119000 |
| Q4 FY2024 2024-12-31 | $2M† | -$23M† | -$21M† | -$2.26† | -$7M† | $1M† |
| Q3 FY2024 2024-09-30 | $0 | -$23M | -$21M | -$2.26 | -$16M† | $5M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$25M
- Short-term investments$90M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How KORRO BIO INC looks technically
KORRO BIO INC (KRRO) is trading 19.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 2 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 3 trading days ago. It is 83.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 19.2% below its 200-day average, the long-term trend line — a long-term downtrend | -19.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.51 | $11.51 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.68 | $11.68 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 10.78. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 2 trading days ago — a "death cross", a bearish long-term signal | 2 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 16.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 43.9 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($8.34 to $10.78) — its "stochastic" reading is 45 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 45.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $55.89 | $55.89 |
|---|---|---|
| From the 52-week high | it is 83.1% below its 52-week high (its highest price of the past year) | -83.1% |
| Above the 52-week low | it is 81.4% above its 52-week low (its lowest price of the past year) | +81.4% |
| Below the 52-week high | it is 83.1% below its highest point of the past year | 83.1% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $2918.50 (set on 2021-02-08) | $2918.50 |
| Given back of the 52-week move | over the past year its closes ranged ($5.28 to $51.36), and it has recovered only a small part of its fall from last year’s high — 9% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $33.76 to $35.23. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.0% |
| From the all-time high | it is 99.7% below its all-time high | -99.7% |
| Nearest price level | it is trading 2.8% above a support level at $9.18 — a price it turned at twice since 2026-05-20, most recently on 2026-09-28. Since 2024-10-21 it has 1 such level below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.8% |
| All-time low | its lowest closing price on record is $5.20 (set on 2025-12-02) | $5.20 |
| Above the all-time low | it is 81.4% above its all-time low | +81.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 82% of it) | 18th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.84 between its high and its low — about 8.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.84 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.53 and $10.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.53 – $9.57 – $10.61 |
| Typical daily range (% of price) | its price moves about 8.9% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.9% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges below its 200-day average price (19.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.14× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.1% |
|---|---|---|
| Gap filled | a 2.2% gap down opened on 2026-10-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +11.19% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.8 percentage points (the stock lost 5.8% while the market gained 1.0%) | -6.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 21.5 percentage points (the stock lost 17.9% while the market gained 3.6%) | -21.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 42.4 percentage points (the stock lost 33.9% while the market gained 8.5%) | -42.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 94.2 percentage points (the stock lost 79.6% while the market gained 14.6%) | -94.2% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 25% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.0% of the share price. | -25.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $11.82 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -20.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $11.15 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -15.4% |
Price levels it has turned at before
KRRO last closed at $9.44 on 2026-10-20. Since 2024-10-21 it has turned at 1 price below its last close and 12 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.18 | Support | 2.8% below the last close | turned there twice · 2026-05-20 to 2026-09-28 |
| $9.83 | Resistance | 4.1% above the last close | turned there twice · 2026-03-30 to 2026-07-31 |
| $10.27 | Resistance | 8.8% above the last close | turned there twice · 2025-06-02 to 2026-06-11 |
| $10.79 | Resistance | 14.3% above the last close | turned there twice · 2026-02-12 to 2026-10-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $10.78.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.22 and $4.87 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $10.78.
This reading has stood for 3 trading days, since 2026-10-16.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bullish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$20.20 range $10.00 – $30.00; median $21.50
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KRRO
- Consensus EPS estimate-$1.26 next reporting period, as of 2026-10-17
- Estimate change, 30 days-$0.014 from -$1.25, on 2026-09-12, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Extensive history of operating losses and no approved products; significant future capital requirements to fund R&D and clinical trials.","RNA editing technology is early-stage, limited in clinical data, and lacks defined regulatory guidelines for commercial approval.","High reliance on the success of the proprietary OPERA platform; failure to achieve development milestones could significantly impact the business."]
What changed in the latest 10-Q
AI-assisted comparison of KRRO's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states the EMA granted orphan drug designation for KRRO-121 for patients with UCDs in August 2026.
- Newer filing states the company remains on track to commence a first-in-human trial for KRRO-121 in the second half of 2026.
- Newer filing describes the announcement in May 2026 of KRRO-111 as the development candidate for the potential treatment of AATD.
- Newer filing describes KRRO-111 as a proprietary GalNAc-conjugated REO delivered subcutaneously to liver cells that repairs a pathogenic SNV on AAT mRNA.
- Newer filing states KRRO-111 demonstrated over 90% of AAT transcripts in liver cells corrected, translating into approximately 90% M-AAT protein in preclinical studies.
- Newer filing states in a repeat-dose study in PiZZ mice, KRRO-111 reduced non-inclusion Z-AAT by approximately 95% and reduced pre-existing aggregates by approximately 62% at day 28.
- Newer filing states inclusion-associated Z-AAT was significantly reduced by approximately 62% at day 28, consistent with autophagic clearance of accumulated protein.
- Newer filing describes KRRO-111's potential as a best-in-disease agent improving both lung and liver manifestations of AATD.
- Removed:
- Older filing anticipated a regulatory filing to enable commencement of a first-in-human trial in the second half of 2026.
- Older filing stated the company was on track to announce the AATD development candidate in the second quarter of 2026.
- Reworded:
- Older filing described OPERA as providing delivery of 'oligonucleotides'; newer filing describes delivery of 'RNA-editing oligonucleotides, or REOs'.
- Older filing described 'machine learning optimization of oligonucleotides'; newer filing describes 'machine learning optimization of REOs'.
- Older filing described 'an oligonucleotide-based approach'; newer filing describes 'an REO-based approach'.
- Older filing described KRRO-121 as a 'GalNAc-conjugated RNA editing oligonucleotide'; newer filing describes it as a 'GalNAc-conjugated REO'.
- Older filing stated KRRO-121 is 'designed to generate' a stabilized, de novo GS protein; newer filing states KRRO-121 is 'designed to obviate the need for a functional urea cycle and instead generate' a stabilized, de novo GS protein.
- Older filing described GS as 'a critical enzyme involved in ammonia clearance'; newer filing describes GS as 'a critical enzyme in an alternate pathway involved in ammonia clearance'.
- Older filing described advancing 'early-stage research and development programs highlighted by a GalNac-conjugated oligonucleotide for AATD' with a plan to announce the candidate in Q2 2026; newer filing replaces this with detailed KRRO-111 disclosures.
- Notes:
- The newer filing text is truncated mid-sentence at 'We have incurred significa' and the older filing text is truncated mid-sentence at 'As a resul', so changes after those points cannot be compared.
- The older filing contains financial figures (net losses, accumulated deficit, future expectations) that are not present in the truncated newer excerpt, so these cannot be confirmed as removals.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 14 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-162 buys ($78809) · 14 sells ($1M) — 1 buying, 3 selling insiders
- Last 180 days · read to 2026-10-162 buys ($78809) · 33 sells ($6M) — 1 buying, 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-14. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KRRO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding KRRO as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,447,287
- Reported value $19,075,243
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about KRRO's institutional holders → See what each manager we track holds →
Short interest (FINRA)
KRRO had 1,675,219 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
KRRO had 11.4% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.55 days to cover at the same settlement.
- Reported short interest (shares) 1,675,219
- Short interest (% of shares outstanding) 11.4%
- Prior settlement (shares) 1,551,984
- Reported change 7.94%
- Days to cover (reported) 6.55
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Wave Life Sciences (WVE)
- Beam Therapeutics (BEAM)
- Ionis Pharmaceuticals (IONS)
- Alnylam Pharmaceuticals (ALNY)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
- Prime Medicine (PRME)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KRRO vs…
Frequently asked questions
What does KORRO BIO INC (KRRO) do?
Korro Bio is a biopharmaceutical company developing a new class of genetic medicines using its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform. The company's technology uses RNA-editing oligonucleotides (REOs) to precisely modify mRNA transcripts to repair or create functional proteins, targeting rare and prevalent diseases without permanently altering the DNA.
What sector is KORRO BIO INC (KRRO) in?
KORRO BIO INC (KRRO) is classified in the Health Care sector. Its industry is Biotechnology (RNA Therapeutics). It trades on NASDAQ.
Who are KORRO BIO INC's (KRRO) competitors?
Notable peers of KORRO BIO INC (KRRO) include Wave Life Sciences, Beam Therapeutics, Ionis Pharmaceuticals, Alnylam Pharmaceuticals and Editas Medicine. This peer set is informational only — not financial advice.
Is KORRO BIO INC (KRRO) overbought or oversold right now?
KORRO BIO INC (KRRO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KRRO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.